The impact of 18 weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC) on skeletal muscle composition of female breast cancer patients

Withdrawn

• Conditions: cachexia; loss of muscle mass; 10006291

• Registration Number: NL-OMON37832
• Lead Sponsor: Maxima Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 13

Inclusion Criteria

- Female breast cancer patients
- Age between 30-65 years
- 18-weeks of chemotherapy-treatment with Taxotere/Adriamycin/Cyclophosphamide (TAC)

Exclusion Criteria

- Participation in an exercise rehabilitation program during the study
- Chronic diseases that influence skeletal muscle tissue characteristics, like type 2 diabetes mellitus, chronic obstructive pulmonary disease, chronic heart failure
- Chronic inflammatory disorders, like rheumatoid arthritis, colitis ulcerosa or Crohn*s disease.
- Musculoskeletal disorders that cause an inability to perform the maximal cycling and strength assessment.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary objective of this study is to investigate the impact of 18 weeks of<br /><br>chemotherapy-treatment on markers of skeletal muscle composition (muscle fiber<br /><br>type distribution and cross sectional area, muscle fiber glycogen and fat<br /><br>concentration, muscle fiber capillarization, muscle fiber satellite cell<br /><br>content), and metabolism (muscle citrate synthase, cytochrome c oxidase,<br /><br>succinate dehydrogenase and beta-hydroxyacyl-CoA dehydrogenase activity). These<br /><br>markers will be measured in skeletal muscle biopsies from 13 female breast<br /><br>cancer patients taken from the vastus lateralis muscle before and after<br /><br>chemotherapy. </p><br>